EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes

Molecular Cancer Therapeutics

Volumn 15, Issue 2, 2016, Pages 287-298

  Hernando, Henar ^a   Gelato, Kathy A ^a   Lesche, Ralf ^a   Beckmann, Georg ^a   Koehr, Silke ^a   Otto, Saskia ^a   Steigemann, Patrick ^a   Stresemann, Carlo ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENHANCER OF ZESTE HOMOLOG 2 INHIBITOR; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; HISTONE; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM TUMOR; FEMALE; GROWTH INHIBITION; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR GENE; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; CELL LINE, TUMOR; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MICE; MULTIPLE MYELOMA; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960387939     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0486     Document Type: Article

References (50)

1. Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet 2015;385:2197-208.
2. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012;9:135-43.
3. Joao C, Costa C, Coelho I, Vergueiro MJ, Ferreira M, da Silva MG. Long-term survival in multiple myeloma. Clin Case Rep 2014;2:173-9.
4. Romano A, Conticello C, Cavalli M, Vetro C, La Fauci A, Parrinello NL, et al. Immunological dysregulation in multiple myeloma microenvironment. BioMed Res Int 2014;2014:198539.
5. Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 2013;4:2186-207.
6. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005;24:6269-80.
7. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 2012;31:753-61.
8. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009;41:521-3.
9. Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, et al. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 2014;10:e1004566.
10. Yuan W, Xu M, Huang C, Liu N, Chen S, Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem 2011;286:7983-9.
11. Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t (4;14) (p16;q32) multiple myeloma. Leuk Lymphoma 2006;47:2289-300.
12. Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, Moorman AF, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t (4;14) multiple myeloma. Hum Mol Genet 1998;7:1071-82.
13. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t (4;14) multiple myeloma cells. Blood 2011;117:211-20.
14. Ezponda T, Licht JD. Molecular pathways: deregulation of histoneh3 lysine 27 methylation in cancer-different paths, same destination. Clin Cancer Res 2014;20:5001-8.
15. Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, et al. Polycomb target genes are silenced in multiple myeloma. PLoS ONE 2010;5:e11483.
16. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 2013;110:7922-7.
17. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012;109:21360-5.
18. Bradley WD, Arora S, Busby J, Balasubramanian S, Gehling VS, Nasveschuk CG, et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem Biol 2014;21:1463-75.
19. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014;13:842-54.
20. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-12.
21. Barsotti AM, Ryskin M, Zhong W, Zhang WG, Giannakou A, Loreth C, et al. Epigenetic reprogrammingbytumor-derived EZH2gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Oncotarget 2015;6:2928-38.
22. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethalityby targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 2015;21:231-8.
23. Ding M, Zhang H, Li Z, Wang C, Chen J, Shi L, et al. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Clin Exp Pharmacol Physiol 2015;42:458-64.
24. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol 2013;8:1324-34.
25. Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 2015;125:346-57.
26. McGrath J, Trojer P. Targeting histone lysine methylation in cancer. Pharmacol Ther 2015;150:1-22.
27. Huang Z, Wu H, Chuai S, Xu F, Yan F, Englund N, et al. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Res 2013;73:6277-88.
28. Luense S, Denner P, Fernandez-Montalvan A, Hartung I, Husemann M, Stresemann C, et al. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors. J Biomol Screen 2015;20:190-201.
29. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009;106:5324-9.
30. Matsuo Y, Drexler HG, Harashima A, Okochi A, Hasegawa A, Kojima K, et al. Induction of CD28 on the new myeloma cell line MOLP-8 with t (11;14) (q13;q32) expressing delta/lambda type immunoglobulin. Leuk Res 2004;28:869-77.
31. Pawlyn C, Kaiser MF, Davies FE, Morgan GJ. Current and potential epigenetic targets in multiple myeloma. Epigenomics 2014;6:215-28.
32. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012;119:5782-94.
33. Dimopoulos K, Gimsing P, Gronbaek K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 2014;4:e207.
34. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010;35:323-32.
35. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010;107:20980-5.
36. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013;153:38-55.
37. Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 2013;12:2113-9.
38. Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol 2013;14:R144.
39. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008;27:7274-84.
40. Parvani JG, Schiemann WP. Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Res 2013;15:R72.
41. Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, et al. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. Epub 2014 Feb. 25.
42. Wu Y, Zhang L, Zhang L, Wang Y, Li H, Ren X, et al. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. Int J Oncol 2015;46:2586-94.
43. Zhang J, Cao W, Xu Q, Chen WT. The expression of EMP1 is downregulated in oral squamous cell carcinoma and possibly associated with tumour metastasis. J Clin Pathol 2011;64:25-9.
44. Sun GG, Wang YD, Cui DW, Cheng YJ, Hu WN. EMP1 regulates caspase-9 and VEGFC expression and suppresses prostate cancer cell proliferation and invasion. Tumour Biol 2014;35:3455-62.
45. Sun G, Zhao G, Lu Y, Wang Y, Yang C. Association of EMP1 with gastric carcinoma invasion, survival and prognosis. Int J Oncol 2014;45:1091-8.
46. Herath NI, Boyd AW. The role of Eph receptors and ephrin ligands in colorectal cancer. Int J Cancer 2010;126:2003-11.
47. Cortina C, Palomo-Ponce S, Iglesias M, Fernandez-Masip JL, Vivancos A, Whissell G, et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 2007;39:1376-83.
48. Gadea G, Blangy A. Dock-family exchange factors in cell migration and disease. Eur J Cell Biol 2014;93:466-77.
49. Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, et al. Human schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells. Mol Cell Biol 2015;35:2684-98.
50. Katsoulidis E, Mavrommatis E, Woodard J, Shields MA, Sassano A, Carayol N, et al. Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem 2010;285:40333-41.